AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05170477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-apical surgery
Description: in Gp B apical patency will not be maintained. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration
Study NCT05759936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500mg seaweed
Description: 4 week supplementation of 1 capsule per day of seaweed
Study NCT05759936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 week placebo supplement of 1 capsule per day
Study NCT05592041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banaba Leaf Extract
Description: a herbal extract in the form of Bigel
Study NCT05084079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSII with formula-based initial insulin regimen
Description: Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
Study NCT05084079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CSII with weight-based initial insulin regimen
Description: TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
Study NCT04786730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Doses of centanafadine will be taken once daily in the morning on Days 1 through 14. The fixed dose strengths will be administered according to body weight. Up to 12 subjects will be enrolled in the 9 to 12 years age cohorts (Cohorts 1 and 6), up to 8 subjects will be enrolled in each of the 6 to 8 years age cohorts (Cohorts 2 and 3), and up to 5 subjects will be enrolled in each of the 4 to 5 years age cohorts (Cohorts 4 and 5).
Study NCT06177171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given orally
Study NCT06177171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given Orally
Study NCT05722834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOAR intervention
Description: This program intervention will be over 6 weeks and participants will have two group sessions and individual sessions, all conducted by an asthma health coach over Zoom (or phone). The two Zoom group sessions will be recorded so that all the information from the conversations will be maintained and used for research purposes. Additionally, participants will keep track of asthma symptoms and complete surveys at specified time-points (the last one at 6 months after participation).~Primary care physicians will be sent emails regarding the self-management goals of their patients.
Study NCT06457165 — intervention group
Intervention type: DEVICE
Intervention: Difficult Intubation
Description: Noted for each patient.
Study NCT05023785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardio-oncology Rehabilitation (CORE)
Description: Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
Study NCT06345261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DiphenhydrAMINE 50 Mg/mL Injectable Solution
Description: injection of Diphenhydramine 50 Mg/mL
Study NCT06345261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: injection of saline
Study NCT06138600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir Injection [Apretude]
Description: White to slightly pink free flowing suspension suspension for injection contained in a brown coloured vial. Each vial is for single use and does not require dilution prior to administration.
Study NCT06138600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)
Description: TDF/FTC is currently available as standard of care for PrEP in the public sector as per the department of health guidelines.
Study NCT06368414 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Asciminib
Description: that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation
Study NCT04300504 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: observational study
Study NCT06457165 — intervention group
Intervention type: DEVICE
Intervention: Not Difficult Intubation
Description: Noted for each patient.
Study NCT04867200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixiana(D006)
Description: NOAC(Factor Xa inhibitor)
Study NCT04867200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-344
Description: NOAC(Factor Xa inhibitor)
Study NCT05872256 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.045% Tazarotene/0.01% Halobetasol Lotion
Description: FDA approved drug for psoriasis treatment
Study NCT04238611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Lactate microneedle applied on the skin of participant
Study NCT04238611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood lactate measurement
Description: Serum lactate testing through conventional laboratory methods
Study NCT04238611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Description: Standardised aerobic exercise regimen
Study NCT06095544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced recovery for SPK recipients
Description: Pre-operative, perioperative and post-operative were consisted of evidenced-based systematic optimization approaches.
Study NCT05552807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: Administered intravenously
Study NCT05400603 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
Description: The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10\^7 and then 3 x 10\^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10\^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels.
Study NCT05552807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Administered intravenously
Study NCT06495359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunization education program
Description: The content of the immunization education program for parents was created by researchers based on the literature. Expert opinions will be obtained from 7 people who are experts in the fields of child health and disease nursing and public health nursing for the training program. The training program consists of 30 minutes. The education program will be delivered to parents in the form of a 30-minute training session using the face-to-face education model. Interactive education methods that enable parents' participation will be used.
Study NCT06499558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classical Training
Description: Students in the education group will practice family planning education skills in the professional skills laboratory.
Study NCT06499558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Patient Interviews
Description: Students in the standardized patient education group will receive training involving a family planning counseling scenario with standardized patients.
Study NCT05425862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pidnarulex
Description: Pidnarulex is a treatment that is designed to stop the action of a particular protein in the body called Polymerase I, that cancer cells rely on. Laboratory studies show that pidnarulex targets a process involving Polymerase I within cells, which can lead to a decrease in cancer growth. Pidnarulex has been shown to have some anticancer activity in ovarian cancer and haematological cancers.
Study NCT05425862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib belongs to a class of drugs called PARP inhibitors, which is currently being used to treat various types of cancer. Talazoparib blocks the function of PARP, a protein that is involved in repairing DNA in cells. By stopping damaged DNA in cells from being repaired, this will lead to accumulation of DNA damage in the cancer cell and ultimately cancer cell death. Talazoparib has established anticancer activity in breast, ovarian and prostate cancers with underlying DNA repair defects. This class of drug have also been used in combination with other treatments such as radiation or chemotherapy to further increase cell death within the cancer.
Study NCT05415267 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: diphtheria and tetanus toxoids (adsorbed) vaccine
Description: The diphtheria/tetanus toxoids vaccine will be given to participants enrolled into Group 1 as a comparator vaccine to the mRNA COVID-19 booster vaccine with the aim of determining whether the results related to COVID-19 vaccine timing also apply to more traditional protein-based vaccines.
Study NCT05415267 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm
Study NCT04976881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication Reconciliation (MedRec) Tool
Description: Patients will receive a print MedRec tool, generated via the EHR, which includes a list of medications prescribed according to the patient record. Patients are asked to review this list, to add/remove drugs to reflect actual use, to note how they are taking each medication, and to describe any concerns.
Study NCT04976881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider Alert and Decision Support
Description: During the clinic visit, an automated, EHR alert will notify the provider that the patient is a woman of reproductive age with T2DM and should receive counseling on the importance of glycemic control, the use of contraception until glycemic control is achieved, and the benefits of folic acid.
Study NCT04976881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREPSheet
Description: When patients leave an encounter, they will receive a patient-friendly educational material (a.k.a. the PREPSheet) that reviews potential risks of pregnancy in the context of T2DM and highlights the importance of: 1) achieving glycemic control through diabetes self-care, 2) using effective contraception until glycemic control is achieved and pregnancy is desired, 3) discussing medication use with a provider if planning or becoming pregnant, and 4) taking folic acid daily to reduce increased risk of neural tube defects.
Study NCT04976881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging
Description: Within \~5 days of their index clinic visit, intervention patients will begin to receive daily, unidirectional text messages to reinforce diabetes self-care behaviors.
Study NCT06188598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Eating is restricted to an 8-hour window that is the same each day (e.g., 10am - 6pm)
Study NCT05552807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Administered intravenously
Study NCT05552807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Administered intravenously
Study NCT05135039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin 100mg/day/patient
Study NCT05135039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100mg/day/patient
Study NCT06307977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Couples Health Project
Description: A 3-session, couples motivational Interviewing drug use and HIV risk reduction intervention
Study NCT05736185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEP selection
Description: Electric impedance tomography-guided PEEP titration
Study NCT05957731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: Both groups received routine physical therapy, which encompasses various components such as electrotherapy, strength training for both lower and upper limbs, gait training, and occupational therapy.
Study NCT05957731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antagonist contract relax
Description: antagonist contraction i used to improve spasticity and range of motion in stroke patients
Study NCT05957731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: agonist contract relax
Description: agonist contraction is used to improve spasticity and range of motion in stroke patients
Study NCT06133855 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: The experimental group will be treated with an ASA magnetic field device (Automatic PMT Quattro Pro) at a frequency of 50 Hz in addition to the traditional physical therapy program. Each session will consist of 20 minutes of the patient lying prone and exposed to low-intensity 20-gauss PEMF.
Study NCT06133855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program
Description: A traditional physical therapy program will include~Infrared radiation for 20 minutes per session for 3 sessions per week for 4 weeks~Ultrasonic: 1 MHz; continuous mode of application: 1.5 w/cm2 for 5 minutes; 3 sessions per week for 4 weeks.~stretching exercises for the hamstring, calf muscles, and back muscles. 3 sessions per week for 4 weeks~Strengthening exercises for back and abdominal muscles.
Study NCT05819242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Angulus
Description: Smartphone app
Study NCT05395403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement device
Description: The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).
Study NCT05297175 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trammpolin medial meniscus prosthesis
Description: Implantation of the Trammpolin medial meniscus prosthesis in patients with a severe medial meniscus damage
Study NCT05176054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health service program
Description: The program will be implemented into the experimental group, the program has been designed as a three-stage model including hospital management, transition care, and post-acute stage care.
Study NCT06133855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program
Description: A traditional physical therapy program will include~Infrared radiation for 20 minutes per session for 3 sessions per week for 4 weeks~Ultrasonic: 1 MHz; continuous mode of application: 1.5 w/cm2 for 5 minutes; 3 sessions per week for 4 weeks.~stretching exercises for the hamstring, calf muscles, and back muscles. 3 sessions per week for 4 weeks~Strengthening exercises for back and abdominal muscles.
Study NCT04719481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin Sodium 80 MG
Description: daily oral administration of 80mg
Study NCT04719481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily oral administration
Study NCT05087433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises
Description: The trainer performed the PRE exercise online with the nurses. The video recording of the progressive relaxation exercises was shared with the nurses participating in the study on WhatsApp groups. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month. The PRE application was reminded daily from the WhatsApp group for the nurses to apply regularly to the sessions and not to disrupt the sessions. Nurses shared the messages stating that they were doing the PRE application on a daily basis for four weeks on WhatsApp groups.
Study NCT05842941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: DNL343 is administered orally once daily per day for 24 weeks.
Study NCT05842941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo is administered orally once daily per day for 24 weeks.
Study NCT05224440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSMV Sponsorship Initiative
Description: Consistent with preventive, universal and public health approaches to suicide, the VA's TSMV Sponsorship Initiative establishes public-private partnerships with federal and community organizations to provide TSMVs with one-on-one, certified and volunteer sponsors in their post-military hometowns. Sponsors are assigned approximately six months prior to discharge and help TSMVs to accomplish reintegration tasks pre-and post-discharge. After certification, sponsors are assigned to and managed by a community integration coordinator (CIC), which is a local organization. CICs recruit sponsors, manage sponsors and match sponsors with TSMVs moving to the local region. After being matched with a TSMV, sponsors then integrate their skills during regular contact with matched TSMVs and monthly video or in-person sessions and help TSMVs identify SMART goals and develop reintegration action plans and ensure TSMVs attend VA healthcare appointments.
Study NCT04795492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: remote intervention
Description: Medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided. Risk factor modification included lipid control, smoking and drinking cessation, BP monitoring, dietary change keeping a healthy weight and in our trial. There were also a lot of educational materials about coronary heart disease knowledge that were reviewed by cardiologists, and participants were free to provide them whenever and wherever they want.
Study NCT04795492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine outpatient follow-up
Description: Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention.
Study NCT05512312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Esthetic crown lengthening
Description: Conventional Surgical Esthetic Crown Lengthening
Study NCT05512312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computer guided Esthetic crown lengthening
Description: Computer guided Esthetic crown lengthening
Study NCT01233570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
Study NCT05491876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy with breathing exercises and ACBT
Description: Group A got chest physiotherapy with breathing exercises and ACBT
Study NCT05491876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy with breathing exercises
Description: Group B got chest physiotherapy with breathing exercises.
Study NCT04960748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WOMEN FIGHTING TO STOP CERVICAL CANCER
Description: The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.
Study NCT04923633 — intervention group
Intervention type: DEVICE
Intervention: Quantifiable Soft Tissue Manipulation (QSTM)
Description: Quantifiable soft tissue manipulation (QSTM) is a force sensing device system that can be used by a clinician to apply a massaging force while the system monitors objective metrics, i.e., the amount, rate, and angle of force applied.
Study NCT06035536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphony™ plus Off-loading
Description: Application of Symphony™
Study NCT06035536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Dressing comprising of calcium alginate Fibracol
Description: Application of Wound Dressing comprising of calcium alginate Fibracol.